This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
So, we’re pleased to have Arrowhead Research here presenting at the Wedbush Life Sciences Management Access Conference. And let’s presenting for Arrowhead our Research Corporation, which is a public traded company focused on metabolic diseases or obesity another issues is Christopher Anzalone, CEO.
Thanks very much. All right, so Arrowhead is a targeted therapeutics company and we are focused entirely on gaining drugs, where they can be effective AnginaRex towards, those ends we have developed a number of platforms they enable us to target and to deliver multiple therapeutic mortalities. So we saw – we view these platforms in two primary asylums. One is we have the world largest human right peptide targeting library. This was developed at MD Anderson Cancer Center and we will talk about this in the next couple of slides.
We use these to conjugate the drugs to make peptide-drug conjugates or PDCs. Think of these as next generation antibody-drug conjugate or ADC. We also have extremely broad set of RNAi platforms. This was centered around delivery, but we also have broad premium to operate within RNAi chemistries.
These technologies came from a number of different areas primarily through the acquisition of Roche’s RNAi business back in October of 2011. We have a portfolio of delivery systems and however, we have two primary systems both of which are targetable, they are non-lipid. And so with those we can make targeted RNAi therapeutics. Now we can use those also in conjunction with our peptide library to make targeted – to which make peptide targeted RNAi therapeutics.